reports
Lifecore Biomedical to be Added to Nasdaq Biotech Index
Lifecore Biomedical to be Added to Nasdaq Biotech Index CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company’s stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore’s inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025. The Nasdaq Biotechnology Index ...
Lifecore Biomedical Signs CDMO Master Services Agreement with New Larg...
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement wit...
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthca...
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California. Details regarding Lifecore’s participation are as follows: 44th Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, includin...
Epsilon Energy Ltd. Announces the Divestment of Dewey Energy Holdings ...
Epsilon Energy Ltd. Announces the Divestment of Dewey Energy Holdings LLC and the Company’s Asset in the Anadarko Basin HOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced the signing of definitive transaction documents and the coincident closing of a sale of the Company’s wholly owned subsidiary, Dewey Energy Holdings, LLC, which holds the Company’s Western Anadarko basin assets, to an undisclosed private buyer. The assets sold included approximately 813 Mcfe/d (60% natural gas) of production (Q3 2025 figure) and app...
Epsilon Energy Ltd. Announces Quarterly Dividend
Epsilon Energy Ltd. Announces Quarterly Dividend HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that its Board of Directors has declared a dividend of $0.0625 per share of common stock (annualized $0.25/sh) to the shareholders of record at the close of business on December 15, 2025, payable on December 31, 2025. All dividends paid by the Company are “eligible dividends” as defined in subsection 89(1) of the Income Tax Act (Canada), unless indicated otherwise. About Epsilon Epsilon Energy Ltd. is a North American...
Epsilon Announces the Issuance of Contingent Shares as Consideration f...
Epsilon Announces the Issuance of Contingent Shares as Consideration for the Acquisition of Peak BLM Lease LLC HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported the issuance of common shares as consideration in connection with the acquisition of Peak BLM Lease LLC, which closed on November 14, 2025. As contemplated by the membership interest purchase agreement for Peak BLM Lease LLC (“Purchase Agreement”), a copy of which was attached to the Company’s proxy statement filed with the Securities and Exchange Commission ...
Epsilon Announces the Closing of the Acquisitions of the Peak Companie...
Epsilon Announces the Closing of the Acquisitions of the Peak Companies With Assets in the Powder River Basin HOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported the consummation of the previously announced acquisitions of Peak Exploration and Production LLC and Peak BLM Lease LLC (together, the “Peak Companies”) (the “Closing”). The Closing followed a special meeting of the Company’s shareholders held on November 12, 2025, where the Company’s shareholders approved the issuance of common shares in connection with the a...
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical to Participate in Upcoming Investor Conferences CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Jefferies 2025 Global Healthcare Conference – London Details: Paul Josephs, Lifecore’s president and chief executive officer, will deliver a corporate presentation and Lifecore management will parti...
Lifecore Biomedical Reports Financial Results for the Three Months End...
Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update -- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development an...
Epsilon Announces Third Quarter 2025 Results
Epsilon Announces Third Quarter 2025 Results HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported third quarter 2025 financial and operating results. Third Quarter 2025 Highlights: Epsilon - Q3 2025 Q3 2025Q2 2025Q3 2024QoQ%YoY%YTD 2025NRI Production GasMMcf2,1362,7521,304-22%64%7,628OilMbbl394453-11%-26%129NGLMbbl1481778%-18%38TotalMmcfe2,4563,0641,727-20%42%8,629DailyMmcfe/d26.733.718.8 31.6 Revenues$M Gas 4,7586,9101,904-31%150%22,282Oil 2,5112,7253,965-8%-37%8,505NGL 26714533584%-20%799Mid...
Liquidia Corporation to Present at Upcoming Healthcare Investment Conf...
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company’s executive leadership team will be providing updates on the company's business during fireside chats at the following two investor conferences in November: 2025 UBS Global Healthcare Conference on Monday, November 10 beginning at 4:15 p.m. ET in Palm Beach Gardens, F...
Liquidia Corporation Reports Third Quarter 2025 Financial Results and ...
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient starts to dateCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascu...
Lifecore Biomedical to Report Financial Results for the Three Months E...
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 Webcast Scheduled for Thursday, November 6 at 4:30 p.m. Eastern CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team ...
Lifecore Biomedical Selected as New Commercial Manufacturing Partner b...
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manuf...
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-...
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical custom...
Liquidia Corporation to Report Third Quarter 2025 Financial Results on...
Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at . A rebroadcast of the e...
Epsilon Energy Ltd. Schedules Third Quarter 2025 Earnings Release and ...
Epsilon Energy Ltd. Schedules Third Quarter 2025 Earnings Release and Conference Call HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that it will issue its third quarter 2025 earnings release on Wednesday, November 5, 2025 after the market close and host a conference call to discuss its financial and operating results on Thursday, November 6, 2025 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time). Interested parties in the United States and Canada may participate toll-free by dialing (833) 816-1385. Internatio...
Epsilon Announces New and Revised Senior Secured Reserve-Based Revolvi...
Epsilon Announces New and Revised Senior Secured Reserve-Based Revolving Credit Facility HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported the closing of a new and revised senior secured reserve-based revolving credit facility (the “Credit Facility”) with Frost Bank as the administrative agent and Frost Bank and Texas Capital Bank as lenders. The new Credit Facility replaces the Company’s previous credit facility. Term highlights of the Credit Facility: Epsilon Energy USA Inc. and Epsilon Energy Ltd. as co-borrowers...
Lifecore Biomedical to Participate at Upcoming Industry Conferences an...
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. Details of the company’s activities at these events are as follows: 15th Annual Partnership Opportunities in Drug Development (PODD)Conference Dates/Location: October 27-28, 2025, in Boston, MADetails: Ryan Swanson, Ph.D., Lifecore’s director of pro...
Liquidia Corporation to Host R&D Day in New York City on October 28, 2...
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it will host a Research & Development Day (R&D Day) on Tuesday, October 28, 2025, in New York City which will be webcast from 2:00 p.m. to 4:30 p.m. Eastern Standard Time. The event will feature presentations from Liquidia’s management team alongside three key opinion leaders (KOLs) in the treatment...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.